Kallisio
Stentra 3D print
Ricoh USA, Inc. and Kallisio have announced a strategic partnership to manufacture and distribute Stentra, a 510(k)-cleared, patient-specific oral stent designed to improve radiation therapy for head and neck cancer (HNC) patients. Developed using technology exclusively licensed from MD Anderson Cancer Center, Stentra is engineered to protect healthy tissue by precisely displacing and immobilising sensitive areas during treatment.
Ricoh says the device allows for more targeted and effective radiation delivery, and is crucial in minimising side effects and enhancing overall treatment outcomes.
RICOH 3D for Healthcare will utilise its network of FDA-registered 3D printing facilities to produce Stentra, which it says will ensure rapid and efficient distribution to radiation oncology teams nationwide.
“Our collaboration with Kallisio highlights our shared commitment to advancing cancer care by addressing critical needs in toxicity management,” said Gary Turner, Managing Director, RICOH 3D for Healthcare. “Stentra not only protects the tongue and other healthy tissues from exposure to radiation but also enhances the precision of radiation therapy, thereby reducing side effects and improving patient quality of life.”
Read more: Ricoh launches flagship 3D medical device manufacturing facility
Kallisio
Stentra digital model
Starting in October, radiation oncologists will be able to order Stentra through RICOH 3D for Healthcare’s Clinical Applications Specialists.
Rajan Patel, CEO of Kallisio added: “Partnering with RICOH 3D for Healthcare is a natural fit for our mission to transform cancer care. Ricoh's expertise in advanced manufacturing and their robust distribution network, including point-of-care production capabilities and clinical applications team, make them an ideal partner. Together, we can ensure that Stentra reaches radiation oncology teams efficiently, enhancing treatment precision and patient outcomes on a broad scale.”
RICOH 3D for Healthcare and Kallisio will be showcasing Stentra at the ASTRO 2024 Annual Meeting, held at the Walter E. Washington Convention Center in Washington, D.C., from September 29 to October 2, 2024. The companies are inviting radiation oncologists and healthcare professionals to visit Booth #801 to experience firsthand demonstrations of Stentra and learn more about its application in improving cancer care.
Kallisio
Diagram of the Stentra device in a patient
